NuPathe

^{, Nasdaq: PATH.XX}

Specialty pharma seeking approval for Zelrix, a patch for migraine treatment.

Industry: Health Care

First Day Return: -3.9%

PATH.XX

Specialty pharma seeking approval for Zelrix, a patch for migraine treatment.

IPO News for NuPathe

NuPathe quiet period ends September 14 09/09/10
NuPathe prices IPO at $10, below the range 08/06/10
NuPathe significantly reduces proposed IPO deal size 08/05/10

IPO Data
IPO Date	08/05/2010
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$50
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.nupathe.com
Headquarters	Conshohocken, PA, United States
Founded	2005
Employees at IPO	22

IPO News for NuPathe

NuPathe quiet period ends September 14 09/09/10
NuPathe prices IPO at $10, below the range 08/06/10
NuPathe significantly reduces proposed IPO deal size 08/05/10

NuPathe (PATH.XX) Performance